Full TitleTreatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment
Hepatoblastoma is a type of cancer that occurs in the liver. It usually occurs in children less than 3 years of age. If left untreated, hepatoblastoma can spread (metastasize) from the liver to other organs in the body, such as the lymph nodes and lungs.
The purpose of this Children’s Oncology Group study is to learn more about the factors that lead to a good or a poor chance of recovery (prognosis) for children with hepatoblastoma. Researchers want to use this information to develop treatments that will increase the overall success rate (eliminate the cancer and not have it return) and decrease the side effects of treatment. Among the questions they are seeking to answer are:
- Are there other factors that are present in children with hepatoblastoma that can be used to develop better treatments?
- Can surgery alone cure children with very low risk hepatoblastoma?
- Can a rating system called Pretreatment Extent of Disease (PRETEXT) be used to decide if a tumor can be removed by surgery?
- Can doxorubicin (chemotherapy) be given with regular chemotherapy without causing too many side effects?
- Is it possible for all patients who need a liver transplant to meet with a liver transplant specialist after the second round of chemotherapy, and can the transplant take place after the fourth cycle of chemotherapy?
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must be newly diagnosed with hepatoblastoma.
- Patients may have had surgery, but no other treatment for hepatoblastoma.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- Patients must be under age 21.
For more information about this study and to inquire about eligibility, please contact Dr. Rachel Kobos at 212-639-8451.